Who are Ongentys's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Comtan, Ongentys, Dibromoxin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bia-9-1067.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ongentys — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ongentys (BIA 9-1067) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Catechol-O-Methyltransferase Inhibitor [EPC]. Area: Metabolic.

marketed Catechol-O-Methyltransferase Inhibitor [EPC] Catechol O-methyltransferase Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Ongentys (BIA 9-1067) — Neurocrine Biosciences. Ongentys works by blocking the enzyme that breaks down dopamine, allowing more dopamine to be available in the brain.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ongentys TARGET	BIA 9-1067	Neurocrine Biosciences	marketed	Catechol-O-Methyltransferase Inhibitor [EPC]	Catechol O-methyltransferase	2020-01-01
Comtan	ENTACAPONE	Orion Pharma	marketed	Catechol-O-Methyltransferase Inhibitor [EPC]	Catechol O-methyltransferase	1999-01-01
Ongentys	Ongentys	Bial - Portela C S.A.	marketed		Catechol O-methyltransferase, Catechol O-methyltransferase
Dibromoxin	BROXYQUINOLINE		marketed	broxyquinoline	Catechol O-methyltransferase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-26 — Ongentys · 9550759 · US
2027-05-12 — Ongentys · 8907099 · US
2027-10-10 — Ongentys · 9745290 · US
2029-04-02 — Ongentys · 8168793 · US
2029-07-14 — Ongentys · 8524746 · US
2030-03-31 — Ongentys · 10071085 · US
2030-03-31 — Ongentys · 10583130 · US
2032-12-12 — Ongentys · 9630955 · US
2035-05-27 — Ongentys · 10357468 · US

Sponsor landscape (Catechol-O-Methyltransferase Inhibitor [EPC] class)

Neurocrine Biosciences · 1 drug in this class
Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ongentys — Competitive Intelligence Brief. https://druglandscape.com/ci/bia-9-1067. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab